The development of a slew of rationally designed targeted therapies that inhibit vascular endothelial growth factor (VEGF) receptor and mammalian target of rapamycin (mTOR) pathways has contributed to the systemic management of RCC. The gene discussed is MTOR; the disease is renal cell carcinoma.